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Central venous access
• Long-term (>7–10 days) parenteral nutrition (PN) re-
quires central venous access (A).
• Strict indications are required for central venous ac-
cess placement, and the catheter should be removed
as soon as possible (A).
• Catheter type, access technique, and the catheter
position should be selected considering to the antici-
pateddurationofPNaimingatthelowestcomplication
risks (infectious and non-infectious) (A).
Commentary
PNsolutionsareadministeredeitherviaacentralvenous
catheter or over short term via peripheral venous cannu-
lae, depending on the condition of the patient (type of
illness, current state of health etc.), composition of the
infused solution, amount of energy to be administered,
and duration of PN. Accessibility of the venous system
needs to be evaluated considering vascular status,
anatomy, and coagulation status. PN associated compli-
cations such as infections and mechanical problems
result in significantly increased morbidity and mortality
[1], [2]. Regular monitoring of metabolic response to PN
is also required [3]. Any venous access that is no longer
required should be immediately removed [4], [5].
PN is usually administered via a central venous catheter
because of the high osmolarity of nutrient admixtures.
The objective of a central venous catheter (CVC) is to get
access to the vena (V) cava. The tip of the CVCs is often
placed in the superior vena cava. Peripheral and central
venous access sites are available for this placement.
When using central venous access sites, the CVC is in-
serted directly into a large vein close to the heart. The
locationofthecathetertipshouldgenerallyberadiologic-
ally documented; ECG-controlled position monitoring is
possible.
Analternativetocentralvenouscannulationisaperipher-
ally inserted central catheter (PICC) using an ultrasound-
guided cannulation of a peripheral vein in the upper arm
[6]. A technically simpler method is the placement of a
PICC-lineinanelbowveinwithoutultrasoundcontrol,and
advancement of this peripheral catheter to the superior
vena cava. The advantages of these peripheral access
sites are lower rates of acute complications such as
pneumothorax,life-threateningbleedings,etc.Thedisad-
vantage is that local complications (phlebitis etc.) [7],
andlatecomplications,especiallythrombosesandinfec-










selecting the type of catheter. If less than three weeks of
PN are anticipated, then percutaneously inserted cath-
eters(e.g.bymeansofSeldingertechnique)areappropri-
ate [9]. The Seldinger method is favoured as it offers
significant advantages when compared to other tech-
niques: lower risk of injury with cannulation, lower risk of





in neonatal and paediatric patients (C).
Commentary
The supply rate of infusion solutions can be set, with a
high degree of accuracy by using infusion pumps, or by
employing the effects of gravity and setting the infusion
speed via a drop counter. All-in-one solutions should
preferably be administered via an infusion pump. The
advantageofsuchdevicesisaprecisecontroloftheflow
rate, which may enhance PN tolerance.
The drop speed, when using gravity infusions, cannot be
regulated as precisely as with the use of infusion pumps,
resulting in potentially excessive infusion rates. The use
of infusion pumps is generally recommended for infants
and children, to secure a controlled flow rate.
Infectious CVC complications
• CVC cannulation predisposes patients to infectious
complications (A).
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Commentary
Thereisclosecorrelationbetweenlengthofhospitalstay
(LOS) and risk of infection [13], [14], [15]. Thrombotic
complications also depend on LOS [15], [16].
Difficult cannulations, severe infectious underlying ill-
nesses, immune deficiency or cannulations carried out
underemergencyconditionsorbyinexperienceddoctors,
predispose patients to infectious CVC complications in
PE [17], [18], [19].
Blood sampling from a CVC increase the risk of catheter-
associated infections [20], [21], [22], [23], [24].
Patientswithstructuralheartdiseaseandassociatedrisk
factors should receive endocarditis prophylaxis prior to
cannulation.
Used catheter/flush system
• Subcutaneous tunnelled catheters or port systems
should be implanted and used for long-term PN, espe-
cially for home PN (A).
• Port needles should be replaced every three to seven
days (B).
• Routine flushing of non-utilised CVCs or port systems
with heparin is not recommended (A).
• CVC should be flushed with isotonic NaCl solution be-
fore and after PN application (A).
Commentary




® catheters, port systems) are suit-




® catheters are implantable, percu-
taneouslyinsertedvenoussiliconecatheters.Themajority
of tunnelled devices have a short polyester cuff attached
to the catheter that encourages fibrosis, and therefore
anchorage within the subcutaneous tissues, and thus
can prevent bacteria from penetrating [25].
If the CVC is temporarily not in use, it should be flushed
daily with isotonic NaCl solution [26]. A heparin flush
solution is not recommended as no benefits are known
[26], but there is a risk of heparin-induced thrombocyto-
penia (HIT) and incompatibilities.
In 1993, Raad et al. [27] described the non-tunnelled
silastic catheter as a safe and economical alternative to
the surgically implanted systems (tunnelled and port
catheters). Port systems are totally implantable venous
silicone or polyurethane catheters with subcutaneous
reservoirchambersmadeoftitaniumorceramic.Theport
membraneismadeofsilicone,andisonlypuncturedwith
special port cannulae (non-coring port needles). It is rec-
ommended that the port needle be replaced every third
toseventhdayinpatientsreceivinghomePNwithcyclical
nutritional application. The transparent dressing should
bereplacedatsimilarintervals[28],[29],[30],[31],[32].
If no nutrient solution and only drugs (cytostatic) are ad-
ministeredviatheport,theportneedlecanbeleftinsitu
for 2 weeks [33], [34], [35]. Extremely good long-term
usabilityandhighpatientacceptancehavebeenobserved
with correct handling [36]. Numerous prospective, non-
randomised studies show a drop in the infection rate
when using subcutaneous port systems [37], [38]. The
tunnelled CVC (Broviac/Hickman) should be preferred
over the port system for long-term PN administration in
children and teenagers because relatively large flush
volumes are required to flush the infusion chamber.
In a prospective cohort study, the instillation of minocyc-
line ethylene diamine tetraacetate (M-EDTA) (port lock)
significantly reduced rate of infections and thrombosis
in children [39].
Access sites/catheter position
• In adults, the subclavian vein is preferred over the in-
ternaljugularveinoranyotheraccesssitewithrespect
to infection risk (A).
• Inpaediatricpatients,accessthroughthegroinresults
in comparable infection rates that other access sites
(B).
• PN solutions should be administered through a CVC
with its tip positioned in the superior vena cava (C).
Commentary
Clinical research data are still limited with regard to the
insertionsite[40],[41].Percutaneouslyinsertedcatheters
should usually be placed in the superior vena cava. In
adults,femoralcatheterscorrelatewithanincreasedrisk
of thrombosis and catheter-related sepsis and are,
therefore, inappropriate for the administration of PN
solutions[42],[43],[44],[45],[46],[47],[48],[49],[50],
[51], [52]. Access to the superior vena cava can be
achieved through the internal jugular vein, subclavian
vein or a peripheral vein in the arm. Catheters placed
throughthejugularveinareassociatedwithanincreased
rate of local haematomas, arterial damage and catheter-
associated infections as compared to subclavian and
femoralcatheters[53],[54],[55],[56],[57],[58].Onthe
other hand, subclavian catheters are associated with an
increased risk of pneumothorax as compared to jugular
catheters [13], [14], [54], [59], [60], [61].
It has not been conclusively determined whether the tip
of the catheter is better positioned in the superior vena
cava or in the right atrium [62], [63], [64], [65]. However,
pericardialtamponades,cardiacarrhythmia,heartlesions
and thromboses have been described when the catheter
tip has been positioned in the atrium, rendering this an
obsolete position.
The prospective randomised study by Cowl et al. [65]
compared102patientsreceivingPNthroughasubclavian
catheter compared to peripherally inserted CVCs. The
study concluded that peripherally inserted CVCs are as-
sociated with a significantly higher rate of thrombophle-
bitis and placement problems. No differences have been
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and occlusions. These results are in line with those of
other authors [66], [67], [68].
Studies in paediatric patients have shown a lower inci-
dence of mechanical complications with access through
the groin, and the rate of infection is similar to that of
non-femoral access [69], [70], [71].
Control of catheter position
• An x-ray examination should be carried out after every
CVC placement, if the subclavian venous access route
is used, or if there were any complications with regard
to implantation, or if no alternative procedure can be
used to verify the catheter position (B).
• Ultrasound-controlledcatheterpositioningsignificantly
reduces the rate of complications associated with
cannulation (A).




catheter position in the superior vena cava [72], but is
no longer recommended due to the relatively high radi-
ation exposure. A radiological confirmation to ensure
correct position of a CVC is recommended, by some
authors, before commencing PN [73], [74], [75].
Variousmetaanalyseshaveshownthatultrasound-guided
CVC insertion via venous cannulation is clearly superior
toconventionalstandardcatheterplacement,whichuses
fixed anatomical reference points, with regard to the rate
of success and complications [76], [77], [78], [79], [80],
[81]. Another method for confirming the position of the
catheter tip in the superior vena cava or the right atrium
istouseelectrocardiographicallyguidedplacement[82],
[83],inwhichafluid-filledcatheterortheretractedguide
wire [83], [84] are used as an electrode for intravascular
ECG-guidance [85], [86], [87]. Prerequisites are a sinus
rhythm and an ECG device authorised for intracardial
ECG-guidance.Theprocedureisnotrecommendedlimited
for use in left-sided internal jugular vein cannulation be-
cause of limited accuracy [88].
Watters et al. [89] compared 1236 ECG-controlled
placements with 586 fluoroscopically-controlled CVC
placements. Radiological thorax monitoring resulted in
an optimum catheter position in both groups [89]. Other
studies (partly randomised, prospective) show that ECG-
guided CVC placement is a safe method [90], [91], [92],
[93].
Material-related issues
• Catheter material, catheter design, mechanical prop-
erties and anti-infectious potential correlate with the
rate of complications (A).
Commentary
There are strict requirements regarding the materials
used for venous catheters. Catheters must be manufac-
tured from tissue-friendly material, must have a length
classification and be X-ray opaque. Generally, every CVC
representsaforeignbodythatcanresultininflammation,
formation of thromboses, and infections.
Thecathetermaterialmayincreasethrombogenicitywhich
can result in catheter colonisation and catheter-associ-
ated infections [94], [95]. Special attention should be
paidtopotentialreactionsofincompatibilitytothemater-
ial or coatings. The associated thrombogenicity and con-
taminationrate,duetophysicochemicalreactions,ishigh
in catheters made of PVC, polypropylene or polyethylene
butlowincoatedpolyurethanecatheters[62],[96],[97],
[98], [99]. Catheters with a rough surface make it easier
for microorganisms to attach themselves (especially co-
agulase-negativestaphylococci,Pseudomonasaeruginosa
andAcinetobactercalcoaceticus)[62],[94],[100],[101].
Some candida species can produce mucous in the pres-
ence of glucose-based solutions which enables fungal
pathogens to attach themselves easily, and explains the
highrateofinfection[102].Morerecentdataonheparin-
coatedCVCsshowpositiveresultsregardingthereduction
of CVC colonisation by microorganisms [102], [103],
[104], [105]. A few isolated cases of heparin-induced
thrombocytopenia (HIT) using heparin-coated pulmonary
catheters and CVCs have been described in literature
[106], [107].
The catheter used for central venous access should be
as thin as possible and the lumen of the analogous vein
should be as large as possible. The rate of infection with
CVC was reported increases with the number of CVC lu-
mina [108], [109], [110], [111], [112], but there are also
studies showing no increased infection risks with multi-
lumencatheters,especiallyifPNisadministeredthrough
a separate lumen and no blood samples are taken via




• Rigorous asepis must be applied during CVC insertion
(use of mask, cap, sterile gown, sterile gloves).
• Prior to the CVC insertion, the insertion site should be
disinfected, preferably with chlorhexidine (B).





related infections in PN have been reviewed by Attar et
al. [116] and O’Grady et al. [13]. Their recommendations
are to wear a sterile cap, mask, gown and gloves after
hand disinfection, to sufficiently disinfect the skin at the
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idine) as well as to use a sufficiently large, sterile drape
for the cannulation site [117], [118]. The importance of
team training in CVC handling is emphasised [13], [119],
[120].
Skin disinfection with a 2% chlorhexidine gluconate
aqueoussolutionreducedthecolonisationratebymicro-
organismscomparedto10%polyvidon-iodinesolutionor
70% alcohol (residual effect of chlorhexidine) [118]. A
randomised, prospective study showed that other
chlorhexidine preparations (e.g. 0.5% tincture) are not
more effective than the 10% polyvidon-iodine solution
with regards to catheter colonisation [121]. In a study on
newborns, a 0.5% chlorhexidine reduced the catheter
colonisation rate more effectively than polyvidon-iodine
solutions [122]. A multicentric study confirmed that a
chlorhexidine-impregnated polyurethane foam over the
catheterexitsitereducestheriskofCVCcolonisationand
infection [123].
Antibiotic prophylaxis during catheter insertion, for pre-
vention of line-induced infections, is not useful [61],
[124], [125], [126]. The prophylactic use of antibiotic-
containing creams promote resistant flora and fauna,
and should, therefore, not be used [20], [127]. No differ-
encehasbeenobservedincatheter-associatedinfections
when it was covered with gauze or transparent film [20].
Covering the catheter insertion site
• Sterilegauzesorsterile,transparent,semi-permeable
films should be used to cover the catheter insertion
site (A).
Commentary
A large-scale study has compared gauze dressings and
transparent film dressings in peripheral venous access.
The results showed a comparable incidence of phlebitis
and catheter colonisation [98]. This data indicates that
transparent film dressings can remain on the insertion
site throughout the duration of the intravenous therapy,
without the risk of increasing thrombophlebitis [98]. A
meta-analysis confirmed similar results for gauze and
film dressing with regards to catheter-associated risk of
infection in CVC. Film dressings could, however, result in
damppatchesandtheoreticallypromoteinfections[128].
Well-healed insertion sites from tunnelled catheters re-
quire no dressing. A gauze dressing should, preferably,
beusedifthecatheterinsertionsiteisbleedingoroozing
[20], [129], [130], [131], [132]. Dressings that have be-
come wet/damp or loosened should be immediately re-
placed [61], [129], [130].
The recommendation for preferentially using alcohol-
basedskindisinfectants(fast-acting,positiveeffect)when
changing the dressing has to be evaluated against the
warningsofnumerouscathetermanufacturersregarding
potential damage to catheter materials and induction of
breaks by such disinfectants.
Catheter care
• Catheter care in patients with PN should be carried
out by specially trained staff, according to define
standards of care (B).
Commentary
A reduction in catheter-associated infections can be
achieved by specifically trained personnel (training on
indications, insertion and care), and by minimising ma-
nipulationofthecatheter[61],[119],[133],[134],[135],
[136]. Disinfection must be carried out in accordance
with standards of hygiene prior to any manipulation of
the catheter cuff or catheter [20], [21], [137], [138],
[139], [140], [141], [142].
CVC changes
• CVC changes should not be performed routinely, and
if an infection is suspected, no guide wire should be
used for changing a CVC (A).
Commentary
Prophylactic catheter changes over the guide wire do not
result in a drop in the risk of catheter-associated infec-
tions [143], but in an increase [110]. A CVC should not
be routinely changed [13], [114], except for a CVC in-
sertedunderemergencyconditionswhichshouldberein-
serted after the patient’s condition has been stabilised.
A CVC should be replaced when a local infection occurs
at the insertion site, or if a catheter-associated blood-
streaminfectionissuspected,butundersuchconditions
a guide wire technique should not be used [13].
Special catheters
• Antibiotic or silver-coated catheters should only be
used in at-risk patients and high-risk care situations
(A).
Commentary
The rate of catheter-associated infections is reduced
when using CVCs impregnated with chlorhexidine and
silver sulfadiazine or with minocycline and rifampicin as
compared to untreated catheters [20], [118], [144],
[145]. A meta analysis outlines the infection-related
benefits of a CVC impregnated with chlorhexidine-silver
sulfadiazine on the exterior [103], [146], [147], [148].
Catheters coated with minocycline/rifampicin on the in-
side and outside performed even better in a randomised
study [146], [149], [150], [151], [152], [153]. There are
also positive results with silver-impregnated catheter
systems [154], [155], [156].
Coated catheters should be used if the CVC is required
for more than 5 days, and there is also a high risk of in-
fection [13]. The slightly higher costs no longer presents
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tients [150], [157]. There is an indication for coated
catheters in these at-risk patient groups: critically-ill pa-
tients, patients with compromised immune systems,
newborns, infants and children [154].
Anticoagulation
• Alow-dosedoralprophylacticanticoagulantshouldbe
administered to patients with home PN (B).
Commentary
Clinically relevant catheter-associated thromboses are
late complications of long-term PN [63], [64], [65]. Cath-
eter occlusions can occur because of the generation of
fibrin or thrombin build-up or partial or total parietal
thrombosis [158]. Two studies indicated that heparin-
coatedCVCsshoweddisadvantagesregardingthepoten-
tial for developing thrombosis [159], [160]. Prophylaxis
with low-dosage warfarin showed a drop in the risk of
thrombosis [161], [162], but not in oncology patients
[163].Thefavourableeffectofwarfarin(dose:1mg/day)
isconfirmedinthesystematicreviewbyKlerketal.[164],
but it is not confirmed for heparin [165].
Filters
• Theuseofin-linefiltersforremovingparticlesisrecom-
mended for at-risk groups (children, immune-sup-
pressedpatients)butcontroversialinpatientswhoare
not at increased risk (B).
Commentary
Infusion solutions can be contaminated with particles
through the manufacturing process, from the container,
or during the transportation or storage process. Mixing
macronutrients with electrolytes, trace elements and
vitamins can result in further particle contamination (in-
compatibility problems). Patients receiving PN are ex-
posed to potential contamination through container ma-
terials and administration equipment (e.g. plastic
particles) as well as the unintentional introduction of
bacteria and precipitates. The use of filters during PN
administration is effective for the mechanical removal of
larger particles, precipitates, bacteria, fungi, larger lipid
particles and air [166]. However, there has not been an
adequate study to date which confirms that the use of
in-line filters significantly reduces the rates of catheter-
associated infection [20].
The greatest concern regarding particles introduction




highly-concentrated, having better solubility at 2–8°C
than at 37°C, which questions the reliability of filtration.
Ball et al. analysed particle contamination in “ready to
use” application systems. Two admixture samples were
taken from the infusion set immediately before being
administered to the patient and one sample was then
filtered. Both samples were evaluated microscopically.
The results showed that the unfiltered sample contained
significantly more particles [168].
Bethune et al. [166] recommend the use of filters in the
administration of PN to the following at-risk patient
groups:patientswithtotaland/orprolongedPN,patients
with weak immune systems, newborns and children. In
the paper of Ball et al. [168] in-line filters are recom-
mended for all patients receiving PN. The in-line filter
should be placed as close to the patient as is practical.
A 1.2 μm filter is used for lipid-containing AIO admixtures
and should be changed every 24 hours. A 0.2 μm filter
can only be used for non-lipid-containing infusion solu-
tions and should only be replaced after 96 hours [169].
Filters themselves can, however, also cause problems
(e.g. occlusions, adsorption of PN components like micro
elements and drugs, cost of filters).
Currently, there is no proof that in-line filters have any
significant influence on the rate of catheter-associated
septicaemia [170]. Therefore, no recommendation can
be made on their routine use for infection prevention.
There are no legally binding rules for using in-line filters
inPN.GuidancebytheRobertKochInstitute[61]onusing
in-linefiltersarguesagainsttheroutineuseofsuchfilters
for infection prevention purposes, but it does not refer in
any detail to particle infiltration.
Occlusions of the CVC or port system:
measures
• CVC occlusions can be caused by blood clots, precipi-
tations and/or residues of PN solution components,
or drugs administered (A).
• Isotonic NaCl solution should be instilled as an initial
measure (A).
Commentary
Catheter occlusion is the most frequent non-infectious
complication.Understandingandcorrectlyidentifyingthe
potential aetiologies leading to occlusion is extremely
important for the treatment strategy [171].
Occlusions can occur in the form of blood clots or due to
fibrinresidues,especiallyafterbloodsampleshavebeen
taken via the catheter or port systems. As an initial
measure in CVC occlusions, NaCl (0.9%) should be in-
jected after first aspirating the contents of CVC applying
slight pressure. This procedure should be repeated if not
initially successful. If the catheter remains blocked, it
shouldbeflushedwithurokinaseorRTPase(5000IE/mL)
(and left to work for 30–60 minutes), especially if there
is a suspicion of a blood clot [172], [173], [174]. The
catheter should be replaced if none of these measures
are successful.
In individual cases, it is possible that tiny amounts of
blood stick to the catheter wall and cannot be removed
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ground for bacteria and can result in the colonisation of
the catheter system [175], [176].
If no blood sample had been taken from the occluded
system, then it must be assumed that an occlusion has
probably occurred due to residue from the nutrient solu-
tion components. Lipid residues can result in CVC occlu-
sions. These usually take a few days to form [177]. In
thesecases,itmaybeeffectivetoinstilsodiumhydroxide
(NaOH: 0.1 mmol/ml, 0.1 M, pH 13) [178]. Flushing with
alcohol (ethanol 96%) should not be carried out, as ac-
cordingtosiliconecathetermanufacturers,alcoholimme-
diately changes the surface of such catheters.
Insoluble precipitates develop with the administration of
drugs and electrolytes like calcium or phosphates. Pre-
cipitates can be caused by incompatibilities between
these components e.g. by the formation of insoluble
crystals [179]. Calcium phosphate precipitates are of
specialsignificance,andareinfluencedbyvariousfactors
in the admixture like amino acid composition, relative
calcium and phosphate content, pH etc. [180], [181]. A





Infection of the CVC or port system
Flow diagram on suspicion of catheter-induced blood-
streaminfection(seeFigure1)[186],[187],[188],[189].
• If catheter infection is suspected peripheral blood-
culture samples, and culture samples from each
catheter lumen should be taken simultaneously (A).
• RemovaloftheCVCshouldbecarriedoutimmediately




Bacterial or fungal colonisation of a CVC is a potentially
life threatening complication of PN as an infection of the
vascularbedwiththeriskofcomplicationssuchasseptic
thrombosis, infectious colonisation of other organs and
endocarditis[190].Catheter-relatedsepsisoccursin5–8
of 1000 patient days and is associated with increased
morbidity,mortalityandmedicalcosts[20],[127],[191],
[192].
If catheter infection is suspected and any resulting com-
plications, the guidelines for antimicrobial therapy for
catheter infections, which have been drawn up by the
Paul Ehrlich society, should be observed.
It is not always easy to diagnose a catheter-associated
infection by using only clinical parameters. In order to
substantiatethesuspecteddiagnosis,CVCbloodcultures
(in multi-lumen catheters, two blood-culture samples
drawn from each catheter lumen) [193] and peripherally
drawnbloodcultures(collectedfromtwoseparatevenous
cannulation sites) must be obtained (Figure 1); they
should be taken at a maximum of 2 hours apart [187],
[188], [189], [194]. However, the decision to remove the
catheter(withtheexceptionofsubcutaneouslyimplanted
permanent catheters [195]) should be taken according
to clinical criteria, and does not depend exclusively on
the results of the microbiological tests.
The catheter must be removed if there are clear and
definitive signs of local infection (e.g. purulent secretion
at the exit site). Although, the removed catheter tip can
becomecontaminatedbythisprocedure,aroutinemicro-
biological test should still be carried out. Systemic antibi-
otic treatment (AB) should be started and adapted, if
necessary, after receiving the culture and antibiotic
sensitivity results. In exceptional cases, and in the ab-
sence of an immediate threat (subclinical infection),
treatment with systemic antibiotics can be attempted
without removing the catheter, especially if the removal
of the catheter (special subcutaneously implanted per-
manentcatheter)ortheresultingconsequencesarelikely
tobeproblematic[20].Potentialadvantagesordisadvan-
tages of catheter removal should be considered in
decision-makinginindividualpatients,e.g.thoseonlong-
term home PN [196], [197].
In the absence of local signs of infection and in clinically
stable patients (subclinical infection), the catheter is left
in situ temporarily. Systemic antibiotic therapy should be
providedandPNcontinued.Inpatientswithsignsofacute
sepsis (acute rise in temperature with new clinical
symptoms), organ dysfunction and/or haemodynamic
instability(e.g.systolicbloodpressure<90mmHgordrop
in systolic blood pressure of ≥40 mmHg relative to initial
value, or a mean arterial pressure <60 mmHg, or the
need for blood pressure lowering drugs), the catheter
must be removed. The tip should be sent for microbio-
logical tests and a new catheter inserted at another ap-
propriate site [198]. In these cases, a systemic antibiotic
therapy must be commenced. Guidelines are available
regarding further adjuvant therapy for sepsis (diagnostic
andtherapyofsepsis–no.079/001–http://www.awmf-
leitlinien.de/)
Evaluation of blood culture results
If peripheral blood cultures are negative with subclinical
signs of infection, but blood cultures from the CVC are
positive, and if other sources of inflammation can be ex-
cluded or are unlikely from a clinical point of view, the
CVC should be removed and the patient treated with
antibiotics. If blood cultures drawn from both the periph-
eral veins and CVC are positive, or there are subclinical
signsofinfection,atemporary(non-tunnelled)CVCshould
always be removed. This particularly applies to patients
with artificial heart valves [199], [200], [201] and to in-
fections with Staphylococcus aureus or candida species.
Systemic antibiotic therapy should also be commenced
[202], [203], [204]. If there are only subclinical signs of
infection in patients with tunnelled CVCs, as in port sys-
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supplementary antibiotic lock treatment and systemic
antibiotictherapyshouldbestarted[205],[206].Surgical
removal of the port system must be considered if these
measures have no effect. Complicated infections with
acute symptoms present high-risk situations regardless
ofbloodcultureresults[207],[208],[209],[210].Insuch
cases the catheter must be removed as quickly as pos-
sibleandsystemicantibiotictherapystarted,evenbefore
thebloodcultureresultsarereceived[202],[208],[209],
[210], [211]. This particularly applies to secondary com-
plications (septic thrombosis, septic embolisms or endo-
carditis), and also inpatients with tunnel or port system
infections or with artificial heart valves [202], [207].
In addition to the systemic antibiotics and within the
frameworkofananticipativestrategy,afurtherantibiotic
lock treatment can be applied to tunnelled CVCs or port
systems and intraluminal catheter colonisation with
staphylococci,enterobacteriaceae,gram-negativebacteria
or fungi in the absence of blood culture infection [212],
[213], [214]. A series of studies have shown that
aminoglycosidesorpenicillincanhaveafavourableeffect,
similar to expensive third generation cephalosporins,
leading to a drop in bacterial colonisation [215], [216],
[217], [218]. Positive clinical experiences have been ob-
served with the administration of vancomycin (3 ml:
2 mg/ml) or a mixture of garamycin (0.5 mg/ml) and
vancomycin (1.0 mg/ml) [219], [220].
Henricksonetal.randomised126paediatriconcological
patients with tunnelled CVCs to a prophylactic lock treat-
ment using three substances [221]. The first patient
group received heparin (10 U/ml), the second group re-
ceivedheparinandvancomycin(25µg/ml),andthethird
group received heparin, vancomycin and ciprofloxacin
(2 µg/ml). The use of vancomycin-ciprofloxacin signific-
antly reduced catheter-associated infections relative to
the group receiving only heparin (p=0.005). A similar be-
neficial effect was observed by using vancomycin lock
treatment (p=0.004).
An antibiotic lock solution does not represent a routine
procedure, but makes sense in patients requiring long-
termaccess,andiftherearepotentialproblemsregarding
CVC reinsertion [212], [218].
Peripheral venous access
• In adult patients, PN through periperal venous access
can be carried out if the PN is indicated for a short
period (max. 7–10 days) of time and no hyperosmolar
solutions(>800mosm/L)orsolutionswithahightitra-
tion acidity or alkalinity (bicarbonate, TRIS-buffer) are
used (B).
• A peripheral venous catheter (PVC) in adults can re-
maininsituforaslongasitisclinicallyrequiredunless
there are signs of inflammation at the insertion site
(A).
Commentary
Peripheral venous access (PVC) is associated with less
complications than central venous access [222], [223].
PN administered via PVCs can only be used as additional
nutritional support or as a temporary measure, as large
volumes are required to deliver the required nutrients.
Peripheral administration of PN should last for no more
than 7(–10) days as the rate of complications increases
after this time period [224], [225], [226], [227]. There is
nogeneralconsensusregardingtheoptimumPN-compos-
ition,infusiontechniqueorpharmacologicalsupplements,
best suited to PVCs, in peripheral PN. In the absence of
lipids, a limit of 800 mosm/L including potential electro-
lyte supplements should be adhered to. The vein quality
of the patient also has to be taken into consideration.
Thrombophlebitisisoneofthemostsignificantcomplica-
tions limiting peripheral PN. There are many factors in-
volvedinitspathogenesis.Theincidenceofthrombophle-
bitisdependsonosmolarity,pHvalueandinfusionspeed
of the PN solution [228], [229], [230]. Problematic sub-
strates are glucose, amino acids and electrolytes. Earlier
studies have shown that infusion solutions containing
glucose and crystalline amino acids rarely resulted in
phlebitisdespiteanosmolarityof>600mosmol/L[231],
[232].Theglucoseconcentrationshouldnotexceed125
g/L [233]. A maximum osmolarity of 800–1000
mosmol/L is recommended.
No link between hyperosmolality and phlebitis has been
observed in lipid-based mixtures. Kane et al. [234] ran-
domised 36 patients for the peripheral intake of nutrient
solutions with an osmolarity of between 1200 and 1700
mosm/L. They found no difference in the incidence of
phlebitis, although this either could be related to the
catheter diameter and/or the flow rate. Williams et al.
[235]documentedsimilarresultsforlipid-basedsolutions
with 650 mosm/kg or 860 mosm/kg. A phlebitis rate of
7–26% was recorded by McMahon et al. [225], [227],
[236], [237] when lipid-based nutrient solutions with an
osmolarity over 1100 mosm/L were administered.
The pH value of commercial nutrient solutions is approxi-
mately 5 to 6. The acidity is caused by the amino acids
and glucose degradation products which are produced
during sterilisation [238].
The frequently used PN bags made of ethylene-vinyl-
acetate (EVA) are permeable to air; this allows for the
oxidationofnutrients,forexample,ofglucosetogluconic
acid [239]. Experimental studies showed a significant
correlation between increased acidity and an incidence
of phlebitis in different infusion solutions [229], [240],
[241]. Adding a neutralising buffer to infusion solutions
withcrystalloids(normalpH4.0–6.5)resultedinareduc-
tion in the rate of phlebitis [238]. There are, however, no
significant clinical studies supporting the routine use of
buffer supplements in peripheral PN. Furthermore, the
effectsofthesesupplementsonthestabilityofPNwould
bedifficulttoassess.Inaddition,theaminoacidmixtures
themselves have a buffer effect (pK values).
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LOS of over 3 days was postulated earlier [99], [242],
more recent studies show that the time-specific risk of
an obstruction, phlebitis and catheter colonisation re-
mains the same even in longer LOS [243], [244], [245].
Peripheral venous catheters can, therefore, remain in
place as long as they are clinically required [61], [243].
In children, peripheral access may be left for the total
duration of intravenous administration and only be
changedifcomplicationsarise[245],[246],[247],[248].
The risk of phlebitis is lower when the cannula is placed
onthebackofthehandcomparedtovenousaccesssites
in the wrist or upper arm [249].
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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